New York City, NY -- (SBWIRE) -- 12/16/2013 -- StockMarketIntel.com issues a special report on the following stocks: Thompson Creek Metals Company Inc (USA) (NYSE:TC), Infinity Pharmaceuticals Inc. (NASDAQ:INFI), Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Responsys Inc (NASDAQ:MKTG)
Thompson Creek Metals Company Inc (USA) (NYSE:TC) trading on 887,931 shares, to end the trade at $2.14. If we look at its trading history of the past 52 weeks, the share price suffered a low of $2.10 and was moved to the maximum level of $4.55. The stock changed hands in a range of $2.12 to $2.17, bringing its market capitalization to about $366.91 million. Thompson Creek Metals Company Inc. engages in mining, milling, processing, and marketing of molybdenum products in the United States and Canada. The company operates in three segments: US Operations Molybdenum, Canadian Operations Molybdenum, and Copper-Gold (Development). Its principal properties include the Thompson Creek Mine, an open-pit molybdenum mine and concentrator located in Idaho; the Endako Mine, an open-pit molybdenum mine, concentrator, and roaster in British Columbia; and the Langeloth metallurgical facility in Pennsylvania.
Is TC a Solid Investment at These Levels? Read This Report For Details
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) declined -2.26%, to complete the trading session at $12.96, with a total volume of 887,108 shares. The stock, on average, trades on a volume of 1.22 million shares. In the past 52 weeks, the share price has not declined below $11.57 and above $50.51. It floated in a range of $12.84 to $13.44 during the last trading session, with a beta value of 0.53. Its market capitalization now moved to about $623.20 million. Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to patients for diseases with significant unmet need.
Is it the Right to Grab INFI after the Recent Slump? Get Free Trend Analysis Here
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) recorded a fall of -10.00% and was in a range of $2.83-$3.18 before closing at $2.84. The share price hit its 52-week low of $2.34 and $6.00 was the best price. The stock completed the day with a total volume of 7.42 million shares, versus an average volume of 2.40 million shares. Avanir Pharmaceuticals, Inc., together with its subsidiaries, engages in acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States. It primarily offers NUEDEXTA, a proprietary combination of dextromethorphan and low-dose quinidine for the treatment of pseudobulbar affect; and Docosanol 10% cream, an over-the-counter product for the treatment of cold sores.
Will AVNR Reach the Bottom after Yesterday’s Correction? Find Out Here
Responsys Inc (NASDAQ:MKTG) added 0.21%, bringing its market capitalization around $992.98 million. The total number of shares that changed hands during the session was 559,070 shares, as compared to average trading volume of 446,907 shares. The share price, after opening at $19.37, made a high of $19.70 and hovered above $19.01 to end the day at $19.32. Responsys, Inc. provides email and cross-channel marketing solutions that enable companies to engage in relationship-based marketing across various interactive channels.
What was the Moving Force behind MKTG on Bullish Run? Read This Research Report
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)